Bristol Myers Squibb to Set UK Pricing for Cobenfy at US Levels Amid Ongoing Pressure from Big Pharma

With the September 29 deadline approaching for compliance with President Trump’s Most Favored Nation drug pricing system, Bristol Myers Squibb (BMS) has announced its intention to price the schizophrenia treatment Cobenfy in the U.K. at the same annual list price as in the United States. This decision underscores the ongoing pressure from major pharmaceutical companies to maintain pricing parity across markets, particularly in light of regulatory changes aimed at controlling drug costs.

The implications of BMS’s pricing strategy are significant, as it reflects a broader trend among pharmaceutical firms to resist potential price reductions in international markets. By aligning U.K. prices with those in the U.S., BMS not only reinforces its pricing strategy but also signals to other industry players the potential risks of deviating from established pricing norms. As the industry navigates the complexities of global pricing strategies, stakeholders in regulatory, QA/QC, CMC, sourcing, and portfolio management must remain vigilant to the evolving landscape of drug pricing and its impact on market access.